BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Ciprofibrate
,
rs7903146
,
SNCA
,
Metabolism of xenobiotics
,
Arthritis
,
Kidney
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CDK4
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Fetal lung
Uterus
Peritoneum
Ovary
Microglial cell
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Injury of heart
Disease due to Adenovirus
Disease caused by parasite
Skin cancer
Injury of eye region
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
JM 3100
NQ Y15
5-(6)-carboxyfluorescein diacetate succinimidyl ester
ITF 2357
pyroxamide
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
mir-124
Ahr
PPIE
CLN5
SOD2
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
A comprehensive nanopore sequencing methodology deciphers the complete transcriptional landscape of …
Targeting CDK4 and CDK6 in cancer.
PFKFB3 mediates tubular cell death in cisplatin nephrotoxicity by activating CDK4.
Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer.
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated …
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumo…
A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients W…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ